Diamanti Antonella, Capriati Teresa, Papadatou Bronislava, Knafelz Daniela, Bracci Fiammetta, Corsetti Tiziana, Elia Domenica, Torre Giuliano
Hepatology, Gastroenterology and Nutrition Unit, Bambino Gesù Children's Hospital, Piazza S. Onofrio 4, 00165 Rome, Italy.
Expert Rev Clin Immunol. 2015 Jun;11(6):699-708. doi: 10.1586/1744666X.2015.1027687. Epub 2015 Apr 11.
Thalidomide has anti-inflammatory and anti-angiogenetic activity that makes it suitable for treating inflammatory bowel diseases (IBD). The recent guidelines from the European Crohn's and Colitis Organization/European Society for Pediatric Gastroenterology Hepatology and Nutrition conclude that thalidomide cannot be recommended in refractory pediatric Crohn's disease but that it may be considered in selected cohorts of patients who are not anti-TNFα agent responders. The main adverse effect is the potential teratogenicity that renders the long-term use of thalidomide problematic in young adults due to the strict need for contraceptive use. In short-term use it is relatively safe; the most likely adverse effect is the neuropathy, which is highly reversible in children. So far the use of thalidomide is reported in 223 adult and pediatric IBD patients (206 with Crohn's disease). In the following sections, the authors will discuss efficacy and safety of thalidomide, in the short-term treatment of IBD.
沙利度胺具有抗炎和抗血管生成活性，使其适用于治疗炎症性肠病（IBD）。欧洲克罗恩病和结肠炎组织/欧洲儿科胃肠病学、肝病学和营养学会最近的指南得出结论，沙利度胺不能推荐用于难治性儿童克罗恩病，但对于非抗TNFα药物应答者的特定患者群体可考虑使用。主要不良反应是潜在的致畸性，由于严格需要使用避孕药具，这使得沙利度胺在年轻人中长期使用存在问题。在短期使用中它相对安全；最可能的不良反应是神经病变，在儿童中高度可逆。迄今为止，已有223例成人和儿童IBD患者（206例克罗恩病患者）使用了沙利度胺。在以下各节中，作者将讨论沙利度胺在IBD短期治疗中的疗效和安全性。
